In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
But if not, you'll need to find stocks that hold the potential to pack more punch. The past doesn't predict the future, but ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...
Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...
Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...
Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.82% to $480.33 Thursday, on what proved to be an all-around grim trading ...
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...
25 analysts have shared their evaluations of Vertex Pharmaceuticals (NASDAQ:VRTX) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table ...
Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results